The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance

Richard Stone ,Jorge Sierra,Bruno C Medeiros,Richard A Larson,Guido Marcucci,Rebecca B Klisovic,Gerhard Ehninger,Susan Geyer,Hubert Serve,Clara D Bloomfield,Dietger Niederwieser,Frederick R Appelbaum,Arnold Ganser,Sergio Amadori,Christian Thiede,Richard F Schlenk,Martin S Tallman ,Ben Sanford ,Francesco Lo‐Coco ,Miguel Á Sanz ,Théo De Witte ,Konstanze Döhner ,Sumithra J Mandrekar ,Joseph Brandwein ,Jürgen Krauter ,Andrew H Wei ,Hartmut Döhner

doi:10.1182/blood.v126.23.6.6

The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance

Richard Stone , Jorge Sierra + Show 25 more

https://doi.org/10.1182/blood.v126.23.6.6

Copy DOI

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance

Full Text